Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYP4F2 siRNA
- Development stage
- Preclinical
- Lead developer
- Beth Israel Deaconess Medical Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
CYP4F2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the cytochrome P450 4F2 (CYP4F2) enzyme. CYP4F2 is a primary ω-hydroxylase responsible for the synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) from arachidonic acid. In the context of pancreatic cancer, CYP4F2 is overexpressed and its product, 20-HETE, promotes tumor growth, metastasis, and inflammation by activating Ras and attracting human macrophages. By targeting CYP4F2 mRNA for degradation, this siRNA reduces 20-HETE levels, thereby suppressing primary pancreatic tumor growth and inhibiting the inflammatory stromal compartment. Research indicates that targeting this pathway may offer a novel approach to treating pancreatic cancer by regulating the tumor microenvironment.
- Other names
- siRNA towards CYP4F2CYP4F2-siRNACYP-4F2-siRNACYP 4F2-siRNA
02
Targets
AGO2/RISC (Protein Argonaute-2 and RNA-induced silencing complex components)Innate immune RNA sensorsCYP4F2 (Cytochrome P450 family 4 subfamily F member 2)
Beyond the preview
Go deeper on CYP4F2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYP4F2 siRNA.